Palvella Therapeutics (PVLA)

• Market cap: $1.99B
• 1 day: -7.42%
• 5 days: -0.19%
• 1 month: -9.02%
• 3 months: 8.35%
• 6 months: 74.02%
• Year to date: 38.65%
• 1 year: 280.1%
• 5 years: -50.63%
• 10 years: -1.81%
• Sector: Healthcare
• Industry: Biotechnology

About: Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.

Employees: 29